What to Do If You Have an Adverse Reaction

How to recognize, respond to, and report adverse reactions during a peptide protocol—from common injection site reactions to the warning signs that require immediate medical attention.

Why This Guide Exists

Peptides are not inherently safe just because they are “natural” or “endogenous”—meaning made inside the body. Synthetic or exogenous peptides can produce unexpected effects, drug interactions, or contamination-related problems. And when you’re managing your own protocol—without the monitoring infrastructure of a clinical trial—adverse reactions can be easily overlooked or attributed to something else entirely.

This matters because knowing what to watch for, what’s genuinely expected versus what’s concerning, and when to seek help is a prerequisite to responsible use. The goal isn’t to scare you away from peptides; it’s to equip you with the knowledge to use them safely and to recognize when something has crossed from “manageable side effect” into “stop and evaluate” territory.

This guide covers common and uncommon adverse reactions across the major peptide classes, from GH secretagogues to GLP-1 agonists to emerging compounds like BPC-157 and PT-141. It also addresses a reality that most guides skip: that some adverse reactions may not be from the peptide itself, but from a contaminated or mislabeled product. That distinction matters for deciding whether to pause, adjust, or switch compounds—or whether to report a pharmacy.

The Difference Between Expected Side Effects and Adverse Reactions

Not every unwanted symptom is an adverse reaction. Some effects are pharmacologically predictable and dose-dependent—they’re part of how the peptide works. Others are unexpected, severe, or persistent enough that they suggest the protocol should be paused or stopped. The distinction matters because it determines your next move.

Expected Side Effects

Expected side effects are pharmacologically predictable and generally manageable. Examples include nausea during the first week of a GLP-1 agonist (common and often improves with time or dose adjustment), water retention from a GH secretagogue (dose-dependent and typically resolves), or increased appetite from MK-677 (an unavoidable consequence of ghrelin signaling). These effects are dose-dependent, often improve over time, and rarely require stopping the compound entirely.

Adverse Reactions

Adverse reactions are unexpected, severe, or persistent effects that suggest something has gone wrong. They might include anaphylaxis, signs of pancreatitis, unexplained neurological symptoms, infection at the injection site, or a symptom that worsens despite dose reduction. Adverse reactions are the signal to stop the protocol and contact your provider.

The Gray Zone

Some symptoms live in the middle: persistent fatigue on a GH secretagogue could be normal metabolic adjustment—or it could signal glucose dysregulation that needs investigation. Joint stiffness from a GH secretagogue could be adaptation—or a sign that your IGF-1 level is too high. In the gray zone, the rule is simple: if you’re unsure whether a symptom is expected or concerning, contact your prescriber. That’s what they’re for. This is not a sign of weakness; it’s responsible self-monitoring.

Keep this distinction in mind as you move through the next sections. It will help you calibrate your response—to know when to reduce a dose, when to pause, and when to seek urgent evaluation.

Common Reactions by Compound Class

Different peptides and peptide analogs produce different side effect profiles. Knowing what’s typical for your compound helps you spot what’s atypical.

GH Secretagogues: CJC-1295, Ipamorelin, Sermorelin, Hexarelin, GHRP-2, GHRP-6

• Water retention: Common and dose-dependent. Usually resolves within days to weeks as your body adapts. If it persists or worsens, reduce your dose.
• Increased appetite: Particularly pronounced with GHRP-6 and MK-677 (note: not a peptide, but included here for context). This is a direct effect of ghrelin stimulation and may not resolve with adaptation. Dose reduction can help.
• Joint stiffness or carpal tunnel symptoms: These can signal that IGF-1 is elevated beyond your optimal range. Check your IGF-1 level; if elevated, reduce your dose. This is a real signal, not a side effect to ignore.
• Flushing or warmth at injection: Common with GHRPs (especially GHRP-6), transient, and usually benign. Typically subsides within minutes.
• Elevated fasting glucose: Expected with GH elevation. Do not panic, but do monitor. Check fasting glucose and HbA1c during your protocol. If glucose drifts toward prediabetic range, discuss with your provider about dose adjustment or adding metformin.
• Numbness or tingling in extremities: May indicate GH is too high. Get an IGF-1 level checked; if elevated, reduce your dose. If symptoms persist, contact your provider.

GLP-1 Agonists: Semaglutide, Tirzepatide, Liraglutide

• Nausea: Very common, especially during titration. Often improves over 1-2 weeks as your body adapts. Eating smaller meals, staying hydrated, and ginger or peppermint tea may help. If nausea is severe or doesn’t improve, reduce your dose or slow the titration schedule.
• Vomiting, diarrhea, or constipation: Dose-dependent GI effects. Usually occur early and improve with time. Constipation can be addressed with increased hydration and fiber; diarrhea with soluble fiber and electrolytes. Contact your provider if these persist or are severe.
• Headache: Common in the first 1-2 weeks, usually mild, and typically resolves. Stay hydrated.
• Fatigue: Common during a caloric deficit (which GLP-1s facilitate). Usually improves once you stabilize. Ensure adequate protein and micronutrient intake.
• Hair thinning: Associated with rapid weight loss, not the drug itself. More likely with aggressive caloric deficits. Ensure adequate protein, iron, zinc, and biotin to support hair health.
• Injection site reactions: Redness, itching, mild swelling. Usually mild and resolve within a few hours. Use proper injection technique (see injection-technique guide); alternate sites to avoid repeated irritation.

BPC-157 and TB-500

• Injection site irritation: Mild redness or discomfort at the injection site. Usually resolves within a few hours. Alternate sites to minimize irritation.
• Nausea or headache: Occasional, mild, and usually transient. Typically subside within hours to a day.
• Important note: Adverse event reporting for BPC-157 and TB-500 is extremely limited because there are no completed clinical trials with systematic safety monitoring. These compounds exist largely in a data gap. If you experience any unexpected reaction, report it (see reporting section below).

PT-141 (Bremelanotide)

• Nausea: Very common—listed in the FDA label for approved PT-141. Often manageable and tends to improve. Taking it with a small meal may help.
• Flushing and facial flushing: A direct result of melanocortin receptor activation. Usually transient (15-30 minutes) and resolves.
• Transient blood pressure increase: Documented in trials. Check your blood pressure before using PT-141 and monitor it. If you have hypertension, discuss with your provider before use.
• Headache: Common, usually mild, typically resolves within a few hours.

Topical Peptides: GHK-Cu, Argireline, Collagen Peptides

• Contact dermatitis: Rare, but possible with any topical agent. Stop use if you develop localized rash, itching, or irritation.
• Skin irritation at application site: Mild redness or dryness can occur, especially at high concentrations. Use a smaller amount or apply less frequently.
• Overall: Topical peptides are generally very well tolerated at cosmetic concentrations. Most users experience no adverse effects.

When to Reduce Your Dose vs. When to Stop

The decision to reduce, pause, or discontinue a protocol depends on how severe the symptom is and whether it’s likely to improve on its own or with dose adjustment.

Reduce Your Dose If:

• The symptom is expected for that compound (nausea on GLP-1, water retention on GH secretagogue, flushing on PT-141)
• The symptom is mild to moderate and tolerable
• The symptom is dose-dependent and likely to improve at a lower dose
• You have no other concerning symptoms

Stop Temporarily If:

• You experience an unexpected symptom you don’t recognize
• A symptom worsens despite dose reduction
• You develop multiple symptoms simultaneously (suggesting systemic reaction)
• Any symptom concerns you enough to warrant evaluation
• You need time to contact your provider and discuss next steps

Stop Permanently and Seek Evaluation If:

• You experience any warning signs listed in the next section
• A symptom persists or worsens after stopping the peptide and waiting 24-48 hours
• You develop signs of an allergic reaction or anaphylaxis
• Your provider recommends discontinuation after evaluation

When in doubt, err on the side of caution. Stopping a protocol for a few days to get clarity is always safer than pushing through a symptom that might be serious.

Warning Signs That Require Immediate Medical Attention

This is the most important section of this guide. Some symptoms require immediate evaluation. If you experience any of the following, stop your protocol and seek medical care or call emergency services.

All of these warrant stopping your protocol immediately and contacting a healthcare provider. Do not wait to see if symptoms improve on their own.

What to Do Step by Step

Step 1: Stop the Protocol

If the reaction is concerning, stop your injections immediately. Do not continue the protocol while waiting to see if a symptom resolves on its own—especially if it’s unexpected or worsening.

Step 2: Document Everything

Record the following in writing or in your phone (be detailed—this information helps your provider):

• The name of the compound you were using
• The dose you administered
• The exact time you administered it
• When symptoms started (within minutes, hours, days?)
• A detailed description of each symptom (not just “felt bad,” but “nausea with abdominal cramping,” “tingling in my right hand starting at 2 AM,” etc.)
• Severity on a scale of 1-10
• Whether symptoms are improving, stable, or worsening
• Any other medications or supplements you took that day
• The compounding pharmacy name and lot number if you have it

Step 3: Contact Your Prescribing Provider

Reach out with your documentation. Have the following information ready:

• What compound you were using and at what dose
• Your symptom description and timeline
• When you stopped
• Whether symptoms are improving or worsening since stopping

Your provider can help determine whether this is an expected side effect requiring dose adjustment, an allergic reaction, or something more serious. They may recommend labs, imaging, or urgent evaluation depending on your symptoms.

Step 4: Seek Emergency Care If Necessary

If your symptoms are severe (see warning signs above), go to an urgent care or ER instead of waiting for a callback from your provider. Bring the vial or product with you so emergency staff can identify exactly what compound you used. Write down the compound name clearly on a piece of paper to give them—many ER doctors are unfamiliar with peptides and need this information.

Step 5: Wait Before Restarting

After resolution of symptoms, do not restart the same protocol without discussing it with your provider. Questions you should ask:

• Was this an allergic reaction or a dose-dependent side effect?
• Can I restart at a lower dose?
• Should I try a different compound or a different peptide class altogether?
• Do I need any additional monitoring or testing?
• If the reaction might have been from a contaminated product, should I order from a different pharmacy?

Step 6: Consider Reporting

If your reaction was serious or unexpected, consider reporting it (see next section). Your report contributes to the safety knowledge base for these compounds.

Reporting Adverse Reactions

One of the biggest gaps in peptide safety data is under-reporting of adverse events. Because compounded peptides and experimental compounds (like BPC-157 and TB-500) exist outside traditional regulatory pathways, adverse events are often not systematically captured. This means that serious safety signals may go undetected.

If you experience an adverse reaction, reporting it—even if it seems minor—contributes to the safety knowledge base and helps protect others. Here’s how:

FDA MedWatch

The FDA has a system for reporting adverse events from any medication, including compounded peptides. You can report online at www.fda.gov/medwatch or by calling 1-888-SAFEMEDS. Include:

• The name of the peptide compound
• The dose and route of administration
• The adverse event (detailed description)
• The date of administration and when symptoms started
• The compounding pharmacy name (if applicable)
• Your outcome (resolved, ongoing, etc.)

Your State Pharmacy Board

If you suspect the reaction was caused by a contaminated, mislabeled, or improperly compounded product, report it to your state pharmacy board. This helps regulators monitor pharmacy quality and take action against unsafe compounders. You can find your state board’s contact information online.

Your Telehealth Platform

Most telehealth platforms have adverse event reporting mechanisms. Contact your provider’s platform to report the event. This creates a paper trail and helps the platform monitor safety across their patient population.

Why reporting matters: Reporting is how we build safety data. When many people report similar adverse events, patterns emerge—like a signal that a particular compounding pharmacy is producing contaminated product, or that a specific compound carries an undiscovered risk. Without reports, these signals remain invisible.

The Contamination Possibility: When the Problem Isn’t the Peptide

Not all adverse reactions are caused by the peptide itself. Some are caused by contaminated, mislabeled, or improperly stored products from low-quality compounding pharmacies. Learning to spot this is essential because it changes your clinical decision—you might not abandon the compound, but you might abandon the pharmacy.

Signs That Suggest a Product Quality Issue

• Reaction doesn’t match the known profile of the compound: For example, you get severe neurological symptoms from a topical GHK-Cu product (which should be harmless). This suggests the vial may not contain what the label says.
• Multiple people report the same unusual reaction from the same batch: If you’re in a community or forum and hear that others had identical unexpected reactions using the same pharmacy and lot number, this suggests contamination or mislabeling, not the peptide itself.
• Visible particulate matter, discoloration, or cloudiness in the vial: Peptide solutions should be clear. Cloudiness, particles, or color changes suggest contamination or improper reconstitution.
• The vial has an unusual or unpleasant odor: Most peptides are odorless or nearly so. A strong smell suggests bacterial growth or chemical contamination.
• The vial feels warm or hot when received: Peptides should arrive at room temperature (or cold-packed). Heat exposure can denature them or encourage bacterial growth.

What to Do If You Suspect Contamination

• Stop using the product immediately.
• Save the vial (including the lot number and expiration date).
• Report to the compounding pharmacy and request a refund or replacement from a different lot.
• Report to your state pharmacy board (they take contamination seriously).
• Consider reporting to the FDA via MedWatch.
• Share your experience in relevant communities or forums (factually, without accusation) so others can protect themselves.

Pharmacy Quality Matters

This is why evaluating your compounding pharmacy is so important. A high-quality pharmacy will have third-party testing, transparent lot traceability, proper storage and handling, and responsiveness to quality concerns. If you experience an adverse reaction, it’s worth asking whether the pharmacy or the peptide is to blame—and your provider can help you make that distinction based on your symptoms and the product’s profile. (For more on evaluating pharmacies, see the forthcoming compounding-pharmacy guide.)

Frequently Asked Questions

What’s the most common adverse reaction to peptide injections?

Depends on the compound. For GLP-1 agonists, nausea is by far the most common—affecting up to 70% of users during titration. For GH secretagogues, water retention and increased appetite are most common. For most users, these are dose-dependent and manageable, improving with time or dose adjustment. Truly adverse reactions—unexpected or severe effects—are less common but do occur.

How long should I wait before restarting a protocol after an adverse reaction?

At least until symptoms fully resolve plus 24-48 hours of observation with no return of symptoms. More importantly, wait until you’ve discussed it with your provider. They can determine whether it’s safe to restart at a lower dose, whether a different compound would be safer, or whether you should skip that peptide class altogether. Rushing to restart without medical input could trigger the same reaction again.

Should I go to the ER for a peptide-related adverse reaction?

Only if your symptoms are severe or you’re unsure whether they’re serious. Warning signs that warrant immediate evaluation include severe abdominal pain, difficulty breathing, chest pain, severe headache with vision changes, or signs of infection at the injection site. For mild or moderate symptoms (nausea, mild joint pain, minor injection site irritation), contact your provider or urgent care. If you’re uncertain, it’s safer to err on the side of seeking evaluation.

Can I be allergic to a peptide?

Yes. Allergic reactions to peptides are rare but possible. Signs include hives, itching, swelling (especially of the face, lips, or throat), difficulty breathing, or anaphylaxis. If you suspect an allergic reaction, stop using the peptide and seek medical care. If you experience anaphylaxis (severe throat tightness, difficulty breathing, rapid heartbeat), call 911. After an allergic reaction is confirmed, do not use that peptide again.

What should I tell the ER doctor if I go in for a peptide-related problem?

Be direct and specific. Bring the vial or have the name written down clearly. Say: “I injected [peptide name] at [dose] [time], and I’m experiencing [specific symptoms].” If you don’t know whether it’s a peptide or a research chemical, say that too. Many ER doctors are unfamiliar with peptides, so giving them the vial and a clear timeline of symptoms helps them make a diagnosis. Don’t minimize or exaggerate—just describe what you’re experiencing factually.

Are adverse reactions more common with compounded peptides than branded drugs?

We don’t have direct comparison data because most peptides in clinical use (like branded semaglutide) have undergone formal testing, while compounded peptides have not. What we do know is that compounded peptides carry additional risk of contamination or mislabeling—which can cause reactions unrelated to the peptide itself. This argues for using a reputable compounding pharmacy with quality controls, third-party testing, and proper storage protocols. It does not mean compounded peptides are inherently more dangerous—just that the pharmacy matters more.

How do I report an adverse reaction from a compounded peptide?

Report to the FDA via MedWatch (www.fda.gov/medwatch or 1-888-SAFEMEDS), to your state pharmacy board, and to your telehealth provider. Include the peptide name, dose, date of administration, detailed symptom description, and the pharmacy name and lot number. Reporting takes 10-15 minutes and helps build the safety data that protects other users.